Published on 09/12/2025

SIP/Sterilization Links in Hybrid (SU + SS) Plants

As the demand for biologics, advanced therapy medicinal products (ATMPs), and viral safety continues to evolve, the pharmaceutical industry faces unique challenges in ensuring compliance with regulatory standards. This tutorial provides a comprehensive guide to the validation of sterilization in hybrid (single-use and stainless steel) plants, focusing on aseptic processing, viral clearance validation, and key regulatory frameworks. Through careful planning and execution, pharmaceutical professionals can ensure the efficacy of their processes and the safety of their products.

Understanding Hybrid Systems: The Need for Validation

In hybrid manufacturing facilities, where both stainless steel (SS) and single-use (SU) systems are utilized, the complexity of maintaining sterile environments increases. Hybrid systems are increasingly adopted for their flexibility, efficiency, and ability to minimize cross-contamination. However, they require a robust validation strategy in alignment with regulatory expectations set forth by bodies such as the FDA, EMA, and PIC/S. The validation process encompasses several critical aspects:

• Aseptic controls: Establishing and maintaining aseptic conditions throughout the manufacturing process is imperative.
• Viral clearance validation: Ensuring that any potential viral contaminants are effectively removed during processing.
• Spiking studies: Implementing suitable studies to assess the effectiveness of viral clearance methods.

Understanding these components is essential for QA, QC, and validation professionals responsible for implementing rigorous validation protocols.

Step 1: Establishing Aseptic Controls

Aseptic controls are foundational for any hybrid manufacturing process, particularly when handling biologics. With the introduction of single-use systems, the integration of aseptic practices requires careful consideration. Key steps to establish aseptic controls include:

1.1 Identifying Critical Control Points (CCPs)

Critical control points are segments within the production process where contamination may occur. To mitigate risk, these points should be systematically identified and monitored. Regulatory guidelines suggest implementing real-time monitoring systems to detect potential deviations promptly.

1.2 Designing Workflow and Facility Layout

The design of the facility and workflow is crucial in facilitating aseptic operations. Hybrid plants must be strategically designed to limit cross-contamination between SU and SS systems. Creating clean zones and operational flows that prevent recontamination is vital to maintaining conformity with Aseptic Controls Annex 1.

1.3 Employee Training and Environmental Monitoring

Regular training of personnel handling aseptic processes is critical. Employees should be acquainted with sterile techniques and environmental monitoring procedures. Continuous monitoring of the facility’s cleanroom environment (air, surfaces, and personnel) is essential to confirming that conditions remain within acceptable limits.

Step 2: Implementing Viral Clearance Validation

Viral clearance validation ensures that the manufacturing process can effectively reduce or eliminate viral contaminants. Understanding the various methodologies is essential in establishing a documented validation approach.

2.1 Definitions and Regulatory Expectations

Viral clearance is defined by the ability to remove viral agents from the product. Regulatory agencies such as the EMA outline specific expectations for demonstrating viral safety, including the types of studies required and the parameters to be assessed.

2.2 Establishing a Viral Clearance Plan

The viral clearance plan should encompass the objectives of the validation, the types of viruses of concern, defined viral spiking studies, and methodologies to be employed. It is essential to address both the manufacturing process and the final product.

2.3 Conducting Spiking Studies

Spiking studies are critical to assess the effectiveness of viral clearance measures. These studies involve deliberately introducing viral pathogens into the product to evaluate the removal or inactivation measures implemented in the process. Factors to consider include:

• Selection of representative viruses based on the product and process.
• Maintenance of appropriate inoculum and assessment of inactivation conditions.
• Validation of analytical methods for accurately quantifying viral loads.

Step 3: Addressing the Chain of Identity and Chain of Custody

The chain of identity and chain of custody are critical concepts in the production of biologics and ATMPs, especially in hybrid systems. Ensuring the integrity of product identity at every stage of production is paramount for regulatory compliance.

3.1 Chain of Identity

Chain of Identity (COI) refers to maintaining accurate traces of product lineage throughout production. It is driven by the necessity to correlate starting materials through to the finished product. Therefore, organizations must implement rigorous documentation protocols, ensuring that every step is logged and traceable.

3.2 Chain of Custody

Chain of Custody (COC) focuses on maintaining the integrity of materials and products throughout the manufacturing process. This may include procedures for tracking the handling and storage of samples and product. Documenting transfers, changes in environmental conditions, and personnel interaction with materials is essential to asserting regulatory compliance.

Step 4: Tailoring PPQ and CPV for ATMPs

Process Performance Qualification (PPQ) and Continued Process Verification (CPV) are integral components of a robust validation strategy in hybrid plants. These processes ensure that consistent quality is maintained throughout product lifecycles.

4.1 Defining PPQ Protocols

Creating tailored PPQ protocols for ATMPs involves defining parameters critical to product quality attributes (CQAs), such as potency, identity, and safety. Regulatory agencies, including the FDA, emphasize that PPQ should be adapted to reflect specific risks associated with novel biologics.

4.2 Developing CPV Strategies

Continued Process Verification is essential to ensure that manufacturing practices remain within acceptable limits throughout the product lifecycle. CPV involves regular data collection and analysis to ensure continued compliance with regulatory standards and to promptly identify potential deviations.

Step 5: Compliance with Regulatory Guidelines

In the context of hybrid (SU + SS) plants, compliance with regulatory guidelines is critical at all stages of validation. The guidelines established by the ICH, especially ICH Q5A(R2), provide a framework for the assessment of viral safety, emphasizing the need for comprehensive viral clearance validation strategies.

5.1 Engaging Regulatory Authorities

It is advisable to engage with regulatory authorities throughout the validation process. This engagement ensures an understanding of expectations and enables the identification of potential pitfalls before they impact compliance efforts.

5.2 Staying Abreast of Changes

The landscape of regulatory requirements is continuously evolving. Staying updated on guidance documents and revisions in regulatory frameworks, particularly those affecting ATMPs and hybrid plants, is critical for continued compliance.

Conclusion: The Importance of a Robust Validation Framework

Establishing a robust validation framework in hybrid (SU + SS) plants is imperative for ensuring product quality and compliance with regulatory standards. Through thorough consideration of aseptic controls, viral clearance validation, chain of identity/custody, and tailored process qualifications, pharmaceutical professionals can adeptly navigate the complexities of biologics and ATMP production. Continued collaboration with regulatory agencies and adherence to evolving guidelines will ensure the successful execution of validation initiatives, safeguarding public health and regulatory compliance.